Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Soldà · SciRah

Researcher profile · Semantic Scholar

C. Soldà

Share profile

C. Soldà — researcher profile on SciRah

h-index: 15
Works: 65
Citations: 972

Most-cited papers

Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial
D. Pastorelli, A. Fabricio, P. Giovanis, Simona D'Ippolito +9 more
2018Pharmacological Research125 citations Open access
Semantic Scholar
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
A. Casadei-Gardini, M. Rimini, T. Tada, G. Suda +79 more
2022European Journal of Cancer124 citations Open access
Semantic Scholar
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
M. Rimini, L. Rimassa, K. Ueshima, V. Burgio +73 more
2022ESMO Open119 citations Open access
Semantic Scholar
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
A. Casadei-Gardini, M. Scartozzi, T. Tada, C. Yoo +23 more
2021Liver international (Print)68 citations
Semantic Scholar
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
M. Persano, M. Rimini, T. Tada, G. Suda +75 more
2023European Journal of Cancer54 citations Open access
Semantic Scholar
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
M. Rimini, S. Shimose, S. Lonardi, T. Tada +21 more
2021Hepatology Research44 citations Open access
Semantic Scholar
Immune senescence and cancer in elderly patients: results from an exploratory study.
C. Falci, Ketty Gianesin, G. Sergi, S. Giunco +12 more
2013Experimental Gerontology44 citations Open access
Semantic Scholar
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
M. Rimini, M. Persano, T. Tada, G. Suda +64 more
2023Journal of Cancer Research and Clinical Oncology39 citations Open access
Semantic Scholar
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
V. Burgio, M. Iavarone, G. D. Di Costanzo, F. Marra +33 more
2021Cancer Management and Research36 citations Open access
Semantic Scholar
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
M. Persano, M. Rimini, T. Tada, G. Suda +76 more
2022Journal of Cancer Research and Clinical Oncology28 citations Open access
Semantic Scholar
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
M. Persano, M. Rimini, T. Tada, G. Suda +68 more
2023Oncology26 citations Open access
Semantic Scholar
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
F. Rossari, T. Tada, G. Suda, S. Shimose +70 more
2024Liver Cancer25 citations Open access
Semantic Scholar
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
M. Rimini, V. Burgio, L. Antonuzzo, L. Rimassa +14 more
2023Therapeutic Advances in Medical Oncology21 citations Open access
Semantic Scholar
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
M. Rimini, M. Persano, T. Tada, G. Suda +66 more
2023Targeted oncology21 citations
Semantic Scholar
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
F. Pelizzaro, A. Sammarco, V. Dadduzio, D. Pastorelli +10 more
2019Digestive and Liver Disease21 citations
Semantic Scholar
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
M. Iavarone, E. Alimenti, T. Tada, S. Shimose +41 more
2023Liver Cancer15 citations Open access
Semantic Scholar
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
M. Persano, A. Casadei-Gardini, T. Tada, G. Suda +71 more
2024Oncology13 citations
Semantic Scholar
Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis
O. De Simoni, M. Scarpa, C. Soldà, F. Bergamo +4 more
2022Journal of Clinical Medicine13 citations Open access
Semantic Scholar
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
F. Rossari, T. Tada, G. Suda, S. Shimose +69 more
2023International Journal of Cancer12 citations Open access
Semantic Scholar
Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP).
U. Basso, C. Falci, A. Brunello, Valeria Zafferri +10 more
2011Journal of Clinical Oncology12 citations
Semantic Scholar
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib
M. Rimini, C. Yoo, S. Lonardi, G. Masi +16 more
2021Hepatology Research11 citations
Semantic Scholar
Simultaneous care in oncology: Assessment of benefit in relation to symptoms, sex, and age in 753 patients
A. Galiano, S. Schiavon, M. Nardi, I. Guglieri +19 more
2022Frontiers in Oncology9 citations Open access
Semantic Scholar
Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options
F. Pelizzaro, A. Ferrarese, M. Gambato, A. Zanetto +9 more
2024Hepatoma Research8 citations Open access
Semantic Scholar
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
M. Persano, M. Rimini, T. Tada, G. Suda +71 more
2024Targeted oncology8 citations Open access
Semantic Scholar
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents
C. Falci, M. Dieci, V. Guarneri, C. Soldà +3 more
2014Expert Review of Anticancer Therapy8 citations
Semantic Scholar
P4 Is vulnerable elders survey 13 (VES-13) a sensitive and specific screening tool for identifying vulnerable/frail elderly cancer patients compared to full comprehensive geriatric assessment (CGA)?
C. Falci, U. Basso, P. Fiduccia, A. Brunello +7 more
20098 citations
Semantic Scholar
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab
L. Stella, G. Cabibbo, C. Celsa, R. Ciccia +27 more
2025Liver international (Print)7 citations Open access
Semantic Scholar
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer.
T. Pressiani, R. Balsano, L. Giordano, M. Milella +13 more
2024European Journal of Cancer7 citations Open access
Semantic Scholar
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis
M. Ghidini, F. Petrelli, M. Paccagnella, M. Salati +14 more
2025Cancers6 citations Open access
Semantic Scholar
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
M. Rimini, B. Stefanini, T. Tada, G. Suda +74 more
2024Liver international (Print)6 citations
Semantic Scholar
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
A. Vitale, Jung Sun Kim, G. Cabibbo, A. Casadei-Gardini +90 more
2025Liver Cancer5 citations Open access
Semantic Scholar
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab
B. Stefanini, F. Piscaglia, F. Marra, M. Iavarone +28 more
2025Liver Cancer5 citations Open access
Semantic Scholar
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
F. Tovoli, D. Pallotta, C. Vivaldi, C. Campani +20 more
2024Digestive and Liver Disease5 citations Open access
Semantic Scholar
L41Phase II study of Gemcitabine and Curcumin (Meriva®) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary results
C. Soldà, R. Bardini, C. Sperti, G. Da Dalt +5 more
20154 citations Open access
Semantic Scholar
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab
A. Dalbeni, F. Cattazzo, M. Vicardi, E. Franceschini +35 more
2025Scientific Reports3 citations Open access
Semantic Scholar
Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
O. De Simoni, Luca Dal Santo, M. Scarpa, G. Munari +10 more
2023Current Oncology3 citations Open access
Semantic Scholar
Good and Prolonged Response to Low Dose Capecitabine as Second LineTherapy in a Patient with Advanced Hepatocellular Carcinoma
C. Soldà, G. Lombardi, C. Aliberti, S. Fasolato +2 more
20153 citations Open access
Semantic Scholar
Chemotherapy-Induced Nausea and Vomiting (CINV): the Achilles Heel ofOncologists
C. Soldà, D. Pastorelli
20003 citations Open access
Semantic Scholar
What do cancer patients experience of the simultaneous care clinic? Results of a cross‐sectional study on patient care satisfaction
A. Galiano, A. Feltrin, A. Pambuku, Leda Lo Mauro +7 more
2024Cancer Medicine2 citations Open access
Semantic Scholar
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.
F. Bergamo, G. Munari, K. Cerma, C. Ceccon +16 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Use of Meriva as complementary therapy of locally advanced or metastatic pancreatic cancer (PC) with gemcitabine (GEM).
C. Soldà, C. Sperti, B. Romeo, G. Da Dalt +5 more
20162 citations
Semantic Scholar
P-036Phase II study of gemcitabine and curcumin as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data
C. Soldà, R. Bardini, C. Sperti, G. Da Dalt +5 more
20152 citations Open access
Semantic Scholar
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)
N. Ben Khaled, U. Ehmer, I. Kubisch, Maria Gonzalez-Carmona +36 more
2026Therapeutic Advances in Medical Oncology1 citations Open access
Semantic Scholar
Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study
A. Dalbeni, A. Auriemma, M. Vicardi, F. Cattazzo +14 more
2026Liver Cancer1 citations Open access
Semantic Scholar
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study
Federica Lo Prinzi, F. Rossari, A. De Rosa, C. Vivaldi +24 more
2025Hepatology Research1 citations
Semantic Scholar
A case of locally advanced pancreatic cancer successfully resected after 14 months therapy with gemcitabine and Meriva
C. Soldà, R. Bardini, Francesca Zingales, D. Pastorelli
20161 citations Open access
Semantic Scholar
Tracheal Cancer : A comprehensive Review
C. Soldà, D. Pastorelli, A. Bridda
20151 citations
Semantic Scholar
From Clinical Heterogeneity to National Standardization in Liver Transplantation for Perihilar Cholangiocarcinoma: The LITALHICA Protocol.
E. Gringeri, Alessandro Furlanetto, Eleonora Nieddu, Renato Romagnoli +32 more
2026Transplantation0 citations
Semantic Scholar
FRI-530 Medical management of patients undergoing elective, liverrelated invasive procedures - a novel collaboration model between hepatologists and hepato-biliary surgeons
C. Mangini, F. Giunta, D. Bassi, R. Boetto +8 more
2026Journal of Hepatology0 citations
Semantic Scholar
THU-247 Impact of Hepatocellular Carcinoma on circulating reticulated platelets in patients with and without liver cirrhosis
Pietro Guerra, S. Toffanin, C. Bulato, Antonio Bonato +12 more
2026Journal of Hepatology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Lonardi×21
Invite
S. Lonardi — researcher profile on SciRah
M. Rimini×20
Invite
M. Rimini — researcher profile on SciRah
C. Vivaldi×20
Invite
C. Vivaldi — researcher profile on SciRah
A. Casadei-Gardini×19
Invite
A. Casadei-Gardini — researcher profile on SciRah

×15

Invite

G. Suda — researcher profile on SciRah

Invite

S. Shimose — researcher profile on SciRah

M. Scartozzi×15

Invite

M. Scartozzi — researcher profile on SciRah

Invite

T. Kumada — researcher profile on SciRah

Invite

H. Iwamoto — researcher profile on SciRah

Invite

T. Sho — researcher profile on SciRah

M. Atsukawa×14

Invite

M. Atsukawa — researcher profile on SciRah

Invite

S. Yasuda — researcher profile on SciRah